Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 635-641

  Van Dreden, Patrick ^a   Rousseau, Aurélie ^a   Savoure, Arnaud ^c   Lenormand, Bernard ^b   Fontaine, Sylvianne ^a   Vasse, Marc ^b  

^a Research and Development   (France)

^b IHURBM   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Acute myocardial infarction; Procoagulant phospholipids; Prognosis; Thrombomodulin activity; Tissue factor activity

Indexed keywords

BLOOD CLOTTING FACTOR 7A; D DIMER; FIBRINOGEN; FIBRINOLYTIC AGENT; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MALE; OUTCOME ASSESSMENT; PARAMETER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FEMALE; HEMOSTASIS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOLIPIDS; PROGNOSIS; THROMBOMODULIN; THROMBOPLASTIN;

EID: 70449567210     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832e05dd     Document Type: Article

References (52)

1. Ross. Atherosclerosis. Nature 2000; 407:233-241.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
3. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9:945-955.
4. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76:2178-2181.
5. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, et al. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993; 12:355-359.
6. Boffa MC. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 1996; 26 (Suppl 4):233-243.
7. Makris T. Thrombomodulin levels in patients with arterial hypertension. Am J Med 1997; 103:331.
8. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, et al. Soluble thrombomodulin as predictor of incident coronary heart disease and symptom less carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353:1729-1734.
9. Cella G, Randi ML, Mennen LI, Amiral J, Guize L, Pujol Y, et al. Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet 1999; 354:425.
10. Goldstein MR. Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet 1999; 354:1646-1647.
11. Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombindependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998; 79:371-377.
12. Uehara S, Gotoh K, Handa H. Separation and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. Thromb Res 2001; 104:325-332.
13. Ohlin AK, Larsson K, Hansson M. Soluble Thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005; 3:976-982.
14. Toschi V. Soluble tissue factor and tissue factor pathway inhibitor in cardiovascular disease. J Thromb Haemost 2007; 5:472-474.
15. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769-771.
16. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL. Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood 2002; 99:4475-4485.
17. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326:242-250.
18. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
19. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81:22-26.
20. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99:2908-2913. (Pubitemid 29258979)
21. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134:253-259.
22. He M, Wen Z, He X, Xiong S, Liu F, Xu J, et al. Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases. Thromb Res 2002; 107:223-228.
23. Seljeflot I, Hurlen M, Hole T, Arnesen H. Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res 2003; 111:369-372.
24. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 5:475-482.
25. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79:2004-2010.
26. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26:2594-2604.
27. Exner T, Joseph JE, Connor D, Low J, Ma DDF. Increased procoagulant phospholipid activity in blood from patients with suspected acute coronary syndromes: a pilot study. Blood Coagul Fibrinolysis 2005; 16:375-379.
28. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101:841-843.
29. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145:962-970.
30. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99:3962-3970.
31. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104:2649-2652.
32. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533-537.
33. Folsom AR. Hemostatic risks factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86:366-373.
34. Jy W, Horstman LL, Jimenez JJ, Ahn YS. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2:1842-1843.
35. Dempfle CE, Kontny F, Abildgaard U. Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Thromb Haemost 1999; 81:701-704.
36. Tracy RP. Assays for thrombosis factors: relations to plasma lipids. Am J Clin Nutr 1997; 65:1669S-1673S.
37. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-744.
38. Cucuianu MP, Cristea A, Roman S, Rus H,Missits I, Pechet L. Comparative behaviour of the components of the factor VIII complex in acute myocardial infarction. Thromb Res 1983; 30:487-497.
39. Tanaka M, Suzuki A. Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers. Thromb Res 1994; 76:289-298.
40. Blann AD, Admiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59:115-120.
41. Nilsson TK, Hellsten G, Amiral J. Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 1993; 4:455-458.
42. Jansonn JH, Boman K, Brannstrom M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage. A prospective study in patients receiving long-term anticoagulant treatment. Circulation 1997; 96:2938-2943.
43. Lohi O, Urban S, Freeman M. Diverse substrate recognition mechanisms for rhomboids; thrombomodulin is cleaved by mammalian rhomboids. Curr Biol 2004; 14:236-241.
44. Ohlin AK, Morser J, Ohlin H. Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. Thromb Res 1996; 82:313-322.
45. Lip GY, Lydakis C, Nuttall SL, Landray MJ, Watson RD, Blann AD. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. J Intern Med 2000; 248:316-318.
46. Chan SH, Chen JH, Li YH, Lin LJ, Tsai LM. Increasing postevent plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol 2006; 111:280-285.
47. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82:1047-1052.
48. Olofsson BO, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10:77-82.
49. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94:2057-2063.
50. Ioannidou-Papayannaki E, Lefkos N, Boudonas G, Efthimiadis A, Psirropoulos D, Vogas V, et al. Alterations in the fibrinolytic system components during acute myocardial infarction. Acta Cardiol 2000; 55:247-253.
51. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsoufis C, Marinou K, et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. Int J Cardiol 2007; 115:203-207.
52. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol 2007; 137:36-48.